Functional antagonism of different angiotensin II type I receptor blockers in human arteries.

abstract：PURPOSE:Dofetilide is class III antiarrhythmic agent which prolongs cardiac action potential duration because of selective inhibition of I (Kr), the rapid component of the delayed rectifier K(+) current. Although clinical studies reported on proarrhythmic risk associated with dofetilide treatment, the contributing elec...

journal_title：Cardiovascular drugs and therapy

authors： Osadchii OE

更新日期：2012-12-01 00:00:00

abstract：:This review will present a summary of a description of apoptotic pathways in the heart, followed by ways to measure it and the experimental and clinical evidence for the role of apoptosis in cardiac disease. An evaluation of the effectiveness of pharmacological and other therapeutic interventions in the prevention of ...

journal_title：Cardiovascular drugs and therapy

authors： Neuss M,Crow MT,Chesley A,Lakatta EG

更新日期：2001-11-01 00:00:00

abstract：:The present study was designed to evaluate the effects of oral verapamil and normal diet on regression of atherosclerotic plaque in cholesterol fed rabbits. Forty-three rabbits were separated into 6 groups and studied for 24 weeks. All groups had a cholesterol diet for the first 12 weeks. Group I was then sacrificed a...

journal_title：Cardiovascular drugs and therapy

authors： Sievers RE,Rashid T,Garrett J,Blumlein S,Parmley WW

更新日期：1987-01-01 00:00:00

abstract：:Heart rate variability is a noninvasive indicator of autonomic nervous system activity. The role of the autonomic nervous system in the genesis of atrial or ventricular arrhythmias is now well established. Little is known about the effects of flecainide on heart rate variability in patients with normal heart structure...

journal_title：Cardiovascular drugs and therapy

authors： Fauchier L,Babuty D,Autret ML,Poret P,Cosnay P,Fauchier JP

更新日期：1998-10-01 00:00:00

abstract：INTRODUCTION:Atrial dilatation is commonly associated with atrial fibrillation (AF), but the electrophysiological mechanisms and the implications for anti-arrhythmic therapy are poorly understood. In a model of acute stretch-related AF in isolated rabbit hearts, we evaluated the electrophysiological effects of three di...

journal_title：Cardiovascular drugs and therapy

authors： Kalifa J,Bernard M,Gout B,Bril A,Cozma D,Laurent P,Chalvidan T,Deharo JC,Djiane P,Cozzone P,Maixent JM

更新日期：2007-02-01 00:00:00

abstract：AIMS:We evaluated a generic quality of life (QoL) Functional Status Questionnaire (FSQ), in patients with chronic heart failure (CHF). The FSQ assesses the 3 main dimensions of QoL: physical functioning, mental health and social role. It also includes 6 single item questions about: work status, frequency of social inte...

journal_title：Cardiovascular drugs and therapy

authors： Gallanagh S,Castagno D,Wilson B,Erdmann E,Zannad F,Remme WJ,Lopez-Sendon JL,Lechat P,Follath F,Höglund C,Mareev V,Sadowski Z,Seabra-Gomes RJ,Dargie HJ,McMurray JJ

更新日期：2011-02-01 00:00:00

abstract：INTRODUCTION:Most circulating fatty acids are contained in lipoprotein triglycerides. For the heart to acquire these lipids, they must be broken down into free fatty acids via the enzyme lipoprotein lipase (LpL). Although it has long been known that hearts primarily use esterified fatty acids as fuel, different sources...

journal_title：Cardiovascular drugs and therapy

authors： Noh HL,Yamashita H,Goldberg IJ

更新日期：2006-12-01 00:00:00

abstract：PURPOSE:In addition to lowering hemoglobin A1C, colesevelam has been shown to improve the atherogenic lipoprotein profile of subjects with type 2 diabetes mellitus (T2DM) when used in combination with metformin and/or sulfonylureas. A recent study evaluated the effects of colesevelam as antidiabetes monotherapy in adul...

journal_title：Cardiovascular drugs and therapy

authors： Rosenson RS,Rigby SP,Jones MR,Chou HS

更新日期：2014-06-01 00:00:00

abstract：:Beneficial effects of monotherapy with ACE inhibitors or beta-blockers on hemodynamic function after myocardial infarction are well known. Until now, the effects of combined treatment on cardiac function and energy metabolism have been poorly described. This study examines the effects of combined ramipril and metoprol...

journal_title：Cardiovascular drugs and therapy

authors： Theres HP,Wagner KD,Romberg D,Feig C,Strube S,Leiterer KP,Günther J,Stangl K,Baumann G,Schimke I

更新日期：2000-12-01 00:00:00

abstract：:This article considers the dominant role of trials involving thousands of patients--the mega-trials--in cardiovascular disease. Problems with large trials mean that alternative strategies must be developed to aid the introduction of new drugs. The limitations of meta-analysis, and of trials with combined and surrogate...

journal_title：Cardiovascular drugs and therapy

authors： Hampton JR

更新日期：1997-01-01 00:00:00

abstract：:To evaluate cordiodepressive risks of antiarrhythmic treatment with diprafenone, we monitored, in addition to conventional hemodynamic parameters, end-systolic pressure-volume relations to assess potential negative inotropic effects. Thirteen patients underwent hemodynamic analysis with and without the influence of di...

journal_title：Cardiovascular drugs and therapy

authors： Thormann J,Kramer W,Kremer P,Schlepper M

更新日期：1989-04-01 00:00:00

abstract：:Ca2+ channel antagonists are agents that interact with the voltage-dependent Ca2+ channel in a highly specific way. The prototype agents of cardiovascular importance are verapamil, nifedipine, and diltiazem, in historical order of appearance. These agents all have different molecular structures and bind separately wit...

journal_title：Cardiovascular drugs and therapy

authors： Opie LH

更新日期：1987-12-01 00:00:00

abstract：:The efficacy of a fixed combination of 10 mg nifedipine and 100 mg acebutolol was tested in 21 patients with angiographically proven coronary artery disease (CAD). Ejection fraction (EF), emptying and filling rate (VS and VD), and end-systolic volume (ESV) were assessed by means of radionuclide ventriculography at res...

journal_title：Cardiovascular drugs and therapy

authors： Bauer R,Busch U,Lutilsky L,van de Flierdt E,Langhammer HR,Pabst HW

更新日期：1989-06-01 00:00:00

abstract：PURPOSE:Single- and multiple-dose studies were conducted to assess the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Japanese subjects. METHODS:All studies were single-center, randomized, placebo-controlled, single-blind or double-blind. In an ascending single-dose study, subjects were given a ...

journal_title：Cardiovascular drugs and therapy

authors： Kim SR,Hasunuma T,Sato O,Okada T,Kondo M,Azuma J

更新日期：2011-12-01 00:00:00

abstract：PURPOSE:Platelets are essential for primary hemostasis; however, platelet activation also plays an important proinflammatory role. Inflammation promotes the development of cardiac fibrosis and heart failure induced by hypertension. In this study, we aimed to determine whether inhibiting platelet activation using clopid...

journal_title：Cardiovascular drugs and therapy

authors： Jia LX,Qi GM,Liu O,Li TT,Yang M,Cui W,Zhang WM,Qi YF,Du J

更新日期：2013-12-01 00:00:00

abstract：:Forty-one chronically T. cruzi-infected male adult albino rats with normal resting ECG were submitted to the ajmaline test (1 mg/kg body weight injected into the dorsal vein of the penis). Twenty-one similar noninfected animals served as controls. Ajmaline induced the following ECG alterations in control rats: A decre...

journal_title：Cardiovascular drugs and therapy

authors： Bestetti RB,Soares EG,Sales-Neto VN,Oliveira JS

更新日期：1989-04-01 00:00:00

abstract：:Despite the fact that beta blockers were introduced into clinical practice 25 years ago, new beta blockers with differing kinetic and dynamic profiles continue to be developed and marketed. This overview assesses some of the more extensively studied agents from the point of view of proof of utility and the validity of...

journal_title：Cardiovascular drugs and therapy

authors： Fitzgerald JD

更新日期：1991-06-01 00:00:00

abstract：BACKGROUND:The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting. METHODS:Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induc...

journal_title：Cardiovascular drugs and therapy

authors： Yurista SR,Silljé HHW,van Goor H,Hillebrands JL,Heerspink HJL,de Menezes Montenegro L,Oberdorf-Maass SU,de Boer RA,Westenbrink BD

更新日期：2020-06-01 00:00:00

abstract：:Cilazapril, an angiotensin-converting enzyme inhibitor, and mibefradil, a selective T-type voltage-operated calcium channel blocker, have been shown to prevent neointima formation after vascular injury. The goal of the present study was to evaluate the mechanism of action of both drugs. For this purpose, the influence...

journal_title：Cardiovascular drugs and therapy

authors： Schmitt R,Clozel JP,Iberg N,Bühler FR

更新日期：1996-05-01 00:00:00

abstract：:Though the exact physiology and pathology of lipoprotein(a) [Lp(a)] remains unknown, it has been demonstrated that increased serum Lp(a) levels are correlated with an increased risk of atherosclerotic vascular disease. The effects of lipid-lowering drugs on Lp(a) levels is unclear because of inconsistencies between st...

journal_title：Cardiovascular drugs and therapy

authors： Dobs AS,Prasad M,Goldberg A,Guccione M,Hoover DR

更新日期：1995-10-01 00:00:00

abstract：:The aim of the present study was to investigate the effects of almokalant on sustained reentrant supraventricular tachycardias. Reentrant tachycardias were induced, using transesophageal atrial stimulation, in 82 patients with atrioventricular reentrant tachycardia (n = 54) or AV nodal reentrant tachycardia (n = 28). ...

journal_title：Cardiovascular drugs and therapy

authors： Darpö B,Edvardsson N

更新日期：1997-07-01 00:00:00

abstract：:There is considerable evidence implicating a key role for p38 mitogen-activated protein kinase (MAPK) in ischemic and pharmacological preconditioning against myocardial infarction. However, there have been few, if any, studies examining the role of p38 MAPK in the protection of stunned myocardium. The purpose of this ...

journal_title：Cardiovascular drugs and therapy

authors： Yoshimura Y,Kristo G,Keith BJ,Jahania SA,Mentzer RM Jr,Lasley RD

更新日期：2004-11-01 00:00:00

abstract：AIMS:The primary ain of this study was to investigate the effect of carbachol on ventricular repolarisation in an intact animal heart. METHODS:In five sheep, carbachol was administered to the left circumflex coronary artery (LCX) at 1.0 and 2.5 micromol/ml/min respectively for 3 min. Multiple unipolar ECGs were acquir...

journal_title：Cardiovascular drugs and therapy

authors： Wang L

更新日期：2003-07-01 00:00:00

abstract：PURPOSE:To investigate the associations of diuretics overall, non-potassium-sparing diuretics in specific, and laxative use with cardiovascular mortality (CVM) in subjects with antihypertensive treatment. METHODS:Analyses included 4253 participants, aged 50 to 75 years, from the German ESTHER cohort and 105,359 partic...

journal_title：Cardiovascular drugs and therapy

authors： Hoppe LK,Muhlack DC,Koenig W,Brenner H,Schöttker B

更新日期：2019-10-01 00:00:00

abstract：:Piperanometozine (OPC-8212) is a new, orally effective inotropic agent. To evaluate the efficacy of this agent on systemic hemodynamics and clinical symptoms in patients with congestive heart failure, a multicenter study was performed. Thirty four patients with New York Heart Association (NYHA) functional classes II t...

journal_title：Cardiovascular drugs and therapy

authors： Inoue M,Hori M,Yasuda H,Takishima T,Sugimoto T,Sasayama S,Sakurai T,Nonogi H,Kodama K,Kusukawa R

更新日期：1987-08-01 00:00:00

abstract：:To characterize the effects of OPC-8212, a quinolone inotropic agent, in patients with heart failure, we utilized invasive hemodynamics, exercise testing, 24-hour ambulatory electrocardiograms, and two patient self-assessment questionnaires, before and after 1 month of treatment with OPC-8212, in 17 patients with mode...

journal_title：Cardiovascular drugs and therapy

authors： Kubo SH,Rector TS,Strobeck JE,Cohn JN

更新日期：1988-12-01 00:00:00

abstract：:Epidemiological studies in the seventies have put forward that dietary rather than genetic factors are responsible for the lower incidence of ischemic heart disease in Greenland Inuit and have generated a large body of both in vitro and in vivo experimental studies, exploring the putative favorable effects of fish (oi...

journal_title：Cardiovascular drugs and therapy

authors： Sassen LM,Lamers JM,Verdouw PD

更新日期：1994-04-01 00:00:00

abstract：:Colesevelam hydrochloride (colesevelam) is a novel, potent, bile acid-binding agent that has been shown to lower LDL cholesterol a mean of 19% at a dose of 3.8 g/d. We studied the pharmacokinetics of colesevelam coadministered with six drugs: digoxin and warfarin, agents with narrow therapeutic indices; sustained-rele...

journal_title：Cardiovascular drugs and therapy

authors： Donovan JM,Stypinski D,Stiles MR,Olson TA,Burke SK

更新日期：2000-12-01 00:00:00

abstract：PURPOSE:Protein kinase C alpha (gene: PRKCA) is a key regulator of cardiac contractility. Two genetic variants have recently been discovered to regulate PRKCA expression in failing human heart tissue (rs9909004 [T → C] and rs9303504 [C → G]). The association of those variants with clinical outcomes in patients with hea...

journal_title：Cardiovascular drugs and therapy

authors： Luzum JA,Ting C,Peterson EL,Gui H,Shugg T,Williams LK,Li L,Sadee W,Wang D,Lanfear DE

更新日期：2019-12-01 00:00:00

abstract：:When severely ischemic myocardium is reperfused, prolonged myocardial dysfunction--a phenomenon named myocardial stunning--frequently occurs. Stunning also occurs in a variety of other situations. These include myocardium located adjacent to infarcted tissue, transient increase in myocardial O2 demands in the presence...

journal_title：Cardiovascular drugs and therapy

authors： Braunwald E

更新日期：1991-10-01 00:00:00